Marker Therapeutics, Inc. (MRKR)
NASDAQ: MRKR · IEX Real-Time Price · USD
5.05
-0.46 (-8.44%)
At close: Jul 19, 2024, 4:00 PM
4.990
-0.050 (-1.09%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Company Description
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications.
Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.
The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer.
Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Marker Therapeutics, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Dr. Juan F. Vera M.D. |
Contact Details
Address: 4551 Kennedy Commerce Dr. Houston, Texas 77032 United States | |
| Phone | (713) 400-6400 |
| Website | markertherapeutics.com |
Stock Details
| Ticker Symbol | MRKR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001094038 |
| CUSIP Number | 57055L107 |
| ISIN Number | US57055L2060 |
| Employer ID | 88-0277072 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Juan F. Vera M.D. | Co-Founder, Chief Executive Officer, President, Treasurer and Director |
| Elizabeth Donnelly | Director of Administration |
| Edmund Cheung | Vice President of Human Resources |
| Dr. Nadia Agopyan Ph.D. | Senior Vice President of Regulatory Affairs |
| Dr. Monic Stuart M.D. | Chief Medical Officer |
| Patricia Allison | Head of Clinical Operations |
| Michael J. Loiacono | Secretary |
| Dr. Robert Z. Florkiewicz Sr. | Senior Director of Molecular Biology and Virology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 12, 2024 | 8-K | Current Report |
| May 17, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| May 15, 2024 | 8-K | Current Report |
| May 15, 2024 | 10-Q | Quarterly Report |
| Apr 26, 2024 | ARS | Filing |
| Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 8, 2024 | 8-K | Current Report |
| Mar 26, 2024 | 8-K | Current Report |
| Mar 26, 2024 | 10-K | Annual Report |
| Mar 1, 2024 | 8-K | Current Report |